Sutro Biopharma, Inc. (FRA:S09)
Germany · Delayed Price · Currency is EUR 0.7625
+0.0210 (2.83%)
Last updated: Dec 1, 2025, 9:59 AM CET
Sutro Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| 105.65 | 62.04 | 153.73 | 67.77 | 61.88 | 42.72 | Upgrade | |
Revenue Growth (YoY) | -34.36% | -59.64% | 126.84% | 9.52% | 44.84% | -0.03% | Upgrade |
Cost of Revenue | -38.73 | 12.5 | 11.83 | 10.11 | 104.4 | 76.96 | Upgrade |
Gross Profit | 144.37 | 49.54 | 141.9 | 57.67 | -42.52 | -34.24 | Upgrade |
Selling, General & Admin | 41.39 | 48.45 | 62.58 | 59.54 | 56 | 36.82 | Upgrade |
Research & Development | 239.54 | 239.54 | 168.59 | 127.07 | - | - | Upgrade |
Operating Expenses | 280.93 | 287.99 | 231.18 | 186.61 | 56 | 36.82 | Upgrade |
Operating Income | -136.55 | -238.45 | -89.28 | -128.94 | -98.52 | -71.06 | Upgrade |
Interest Expense | -38.65 | -32.37 | -23.75 | -7.42 | -3.2 | -2.8 | Upgrade |
Interest & Investment Income | 12.48 | 18.64 | 14.51 | 3.46 | 0.58 | 1.51 | Upgrade |
Other Non Operating Income (Expenses) | -2.67 | -5.06 | - | - | 0.06 | -1.17 | Upgrade |
EBT Excluding Unusual Items | -165.4 | -257.24 | -98.52 | -132.91 | -101.08 | -73.52 | Upgrade |
Gain (Loss) on Sale of Investments | - | 32.14 | 9.92 | 16.2 | -4.45 | 41.5 | Upgrade |
Pretax Income | -214.42 | -225.1 | -88.6 | -116.7 | -105.54 | -32.03 | Upgrade |
Income Tax Expense | 2.34 | 2.36 | 18.19 | 2.5 | - | 0.1 | Upgrade |
Net Income | -216.77 | -227.46 | -106.79 | -119.2 | -105.54 | -32.13 | Upgrade |
Net Income to Common | -216.77 | -227.46 | -106.79 | -119.2 | -105.54 | -32.13 | Upgrade |
Shares Outstanding (Basic) | 84 | 77 | 60 | 51 | 46 | 33 | Upgrade |
Shares Outstanding (Diluted) | 84 | 77 | 60 | 51 | 46 | 33 | Upgrade |
Shares Change (YoY) | 17.26% | 27.70% | 18.57% | 10.02% | 41.59% | 41.88% | Upgrade |
EPS (Basic) | -2.59 | -2.96 | -1.78 | -2.35 | -2.29 | -0.99 | Upgrade |
EPS (Diluted) | -2.59 | -2.96 | -1.78 | -2.35 | -2.29 | -0.99 | Upgrade |
Free Cash Flow | -225.11 | -194.64 | -115.93 | -4.31 | -97 | -74.93 | Upgrade |
Free Cash Flow Per Share | -2.69 | -2.53 | -1.93 | -0.09 | -2.10 | -2.30 | Upgrade |
Gross Margin | 136.66% | 79.85% | 92.30% | 85.09% | -68.71% | -80.14% | Upgrade |
Operating Margin | -129.25% | -384.33% | -58.07% | -190.26% | -159.22% | -166.32% | Upgrade |
Profit Margin | -205.18% | -366.62% | -69.47% | -175.89% | -170.55% | -75.20% | Upgrade |
Free Cash Flow Margin | -213.08% | -313.72% | -75.41% | -6.36% | -156.76% | -175.39% | Upgrade |
EBITDA | -128.99 | -231.24 | -82.46 | -123.25 | -93.68 | -66.76 | Upgrade |
EBITDA Margin | -122.09% | - | -53.64% | -181.86% | -151.39% | -156.27% | Upgrade |
D&A For EBITDA | 7.57 | 7.22 | 6.82 | 5.69 | 4.84 | 4.3 | Upgrade |
EBIT | -136.55 | -238.45 | -89.28 | -128.94 | -98.52 | -71.06 | Upgrade |
EBIT Margin | -129.25% | - | -58.07% | -190.26% | -159.22% | -166.32% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.